Careside Inc(CASI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.02 | Insider Own | 87.27% | Shs Outstand | 15.5M | Perf Week | - |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 9.3M | Perf Month | -73.05% |
| Enterprise Value | - | PEG | - | EPS next Q | -0.36 | Inst Own | 32.6% | Short Float | 0.98% | Perf Quarter | -75.4% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.45 | Perf Half Y | -91.09% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.09M | Perf YTD | -75.59% |
| Book/sh | - | P/C | - | EPS past 3/5Y | 1.69% - | ROE | - | 52W High | -93.28% ($3.09) | Perf Year | -91.09% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | -1.67% - | ROIC | - | 52W Low | 0% ($0.21) | Perf 3Y | -88.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -42.26% | Gross Margin | - | Volatility(W/M) | 24.09% 13.06% | Perf 5Y | -99.17% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | 26.2% | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | -97.5% |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 18.41 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | -60.5% | SMA20 | -75.33% ($0.85) | Beta | 1.01 | Target Price | $4 |
| Payout | - | Debt/Eq | - | Earnings | 11000000 | SMA50 | -76.46% ($0.89) | Rel Volume | 0 | Prev Close | $0.21 |
| Employees | 233 | LT Debt/Eq | - | EPS/Sales Surpr. | -70% - | SMA200 | -85.7% ($1.47) | Avg Volume(3M) | 0.20M | Price | $0.21 |
| IPO | 1996/6/12 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
💊 CareSide (ticker CASI) is a clinical-stage biopharmaceutical company developing and commercializing oncology and immunology drugs, with a primary focus on the U.S. and Chinese markets. Its core pipeline centers on an anti-CD38 monoclonal antibody candidate, and its revenue structure combines product sales from already-approved oncology therapies. The company falls within the micro-cap category given its relatively small market capitalization, and its share price tends to exhibit significant volatility depending on clinical development progress and funding conditions.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 32.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GENZ VanEck Digital Native Economy ETF 16M It ranks #558 of 596 in the industry
Based on market cap of $3M.
FAQ
What kind of company is CASI?
CASI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CASI?
The market cap of CASI is approximately $3M, ranking 5,742 within its sector.
What is the 52-week high and low for CASI?
CASI has recorded a 52-week high of $3.09 and a low of $0.21.
